Driver set out on an ambitious mission, make the world's cancer treatments available to all. Today patients only have access to clinical trials of a center that they physically enter, yet there is an unprecedented number of trials taking place. With Driver, a patient's tissue is collected, analysed at Driver's labs and subsequently matched with clinical trials. The patient is guided through a chosen treatment by one of Driver's physicians and once complete, receives follow up care in line with up-to-date National Comprehensive Cancer Network guidelines. Sadly, Driver liquidated as further funding failed to be secured.
ABOVE: ACCESS WORLDWIDE CENTERS WITHOUT LEAVING HOME
Partnering with prestigious institutes around the globe, Driver indexes their respective clinical trials in a standardised format to facilitate treatment matching. With Driver, patients can have their tumor sample tested for eligibility for any of these trials at centers in North America, Europe, or Asia without leaving their home.
ABOVE: INTERACTIVE GLOBE
I created a stylized interactive globe visualising the partner centers. A globe was used to reinforce the value proposition of being able to find potential treatment matches, no matter how far away they may be.
ABOVE: HOW IT WORKS
The products were explained with illustrations that aim to communicate the core idea behind each of the stages in the journey.
Getting or Giving Driver
One of the brand principles is to provide a guided experience and at launch, the Join Driver flow was shared between the app and the website. Because the flow was shared, joining Driver was designed to feel like the first phase of onboarding (where information is collected regarding the patient’s tumor samples and medical records), echoing the Wizard which appears throughout the app that guides users through information collection.
App Home: A Guided Experience
At the core of the app is a guided experience facilitated through the 'Action Board'. Driver's solution to cancer care consists of three services that work together. Hyperdrive matches patients to treatments, Everdrive offers post-treatment care based on the most up to date NCCN guidelines, and DriverOn offers patients access to Drivers network of oncologists without patients ever having to leave their homes. The Action Board provides guidance by surfacing information pertinent to that moment in time relative to the patients journey, prompting the patient to take action through various assessments and reminders and to provide recaps of tasks right after they are completed.
The Wizard: A tool for tasks
The Wizard was conceived of and design to make tasks feel simple, easy, and encourage completion without distraction (by entering a focus mode). The Wizard is a multistep form that is used in joining Driver, collecting medical information about the patient, conducting assessments, find and arrange calls with oncologists, and more. The goal was to make information feel easy and simple to input. We designed a range of different layouts to facilitate varying amounts of options and types of data collected.
Service Dashboards: Medical information in one place
Each of the three services that form Driver's solution to cancer care each has dashboards that are accessible from a global navigation to provide the user the option to access their information, conduct an assessment, or arrange an appointment with an oncologist on their terms. The Action Board is a response to the first insight that cancer care is confusing, overwhelming and complicated, yet the second insight is that patients are motivated by fear and a sense of mortality resulting in a strong desire to be in control, and a strong motivation to get things done at any cost. Access to the dashboards allows users to maintain control over their information and care that they seek.
Hyperdrive: For patients who are seeking treatment
Hyperdrive matches patients to cutting edge clinical trials in a range of institutions without a patient ever having to leave their home. The problem with treatment is that patients only have access to the treatments of a hospital that they physically enter, and those treatments that the oncologist in front of them can remember (unbelievably, we have seen photographs of paper with hand-scribbled notes on what trials are being run). Driver retrieves a patient's tumor sample and medical records from the hospital they are kept at, and analyses the sample in their own labs. Once analysed, the patient is matched with appropriate trials in Driver's database. Driver indexes trials through its partner program and standardises the data to make matching possible. Patients can consult an oncologist in the Driver network that specialises in their cancer, and select an appropriate trial to enroll into.
Everdrive: For patients who have been treated in the past
Everdrive provides care for patients according to the most up to date NCCN guidelines. The problem with providing care is that the guidelines are lengthy yet they provide valuable information regarding prevention and risks for other cancers over time. Everdrive turns these guidelines into prompts for checkups, assessments, and more to ensure that patients are getting the best out of them, without the hassle. Patients have access to Driver's oncologist and nurse network for moments where they require more information and expert opinion.
DriverOn: Access oncologists best suited to your needs
DriverOn provides patients with access to consultations from oncologists that specialise in their type of cancer and from the privacy of their own homes. The problem with consultations and second opinions is that patients can only access oncologists in centers that they physically visit. During this engagement, we discovered the story of a case in China where simply through access to an oncologist with experience and expertise in a rarer type of cancer in children, a child's life was saved thanks to their consultations and ability to understand the scans on a deeper level. Driver aims to tear down the limitations of distance and make consultations like these accessible to more people.